$720 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 75 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | INVESCO QQQ TRput | $86,993,000 | – | 325,500 | +100.0% | 12.08% | – | |
| New | NVIDIA CORPORATIONcall | $20,952,000 | – | 172,600 | +100.0% | 2.91% | – | |
| New | TEVA PHARMACEUTICAL INDS LTDcall | $17,835,000 | – | 2,210,000 | +100.0% | 2.48% | – | |
| BIIB | New | BIOGEN INC | $14,819,000 | – | 55,500 | +100.0% | 2.06% | – |
| New | UNITY SOFTWARE INCcall | $11,709,000 | – | 367,500 | +100.0% | 1.62% | – | |
| PANW | New | PALO ALTO NETWORKS INC | $10,319,000 | – | 63,000 | +100.0% | 1.43% | – |
| WIX | New | WIX COM LTD | $10,092,000 | – | 129,000 | +100.0% | 1.40% | – |
| KRNT | New | KORNIT DIGITAL LTD | $8,593,000 | – | 322,926 | +100.0% | 1.19% | – |
| GLBE | New | GLOBAL E ONLINE LTD | $8,335,000 | – | 311,460 | +100.0% | 1.16% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $8,138,000 | – | 1,052,842 | +100.0% | 1.13% | – |
| ADBE | New | ADOBE SYSTEMS INCORPORATED | $8,022,000 | – | 29,150 | +100.0% | 1.11% | – |
| New | PERION NETWORK LTD | $7,816,000 | – | 405,184 | +100.0% | 1.08% | – | |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $7,193,000 | – | 173,696 | +100.0% | 1.00% | – |
| S | New | SENTINELONE INCcl a | $7,157,000 | – | 280,000 | +100.0% | 0.99% | – |
| ALBO | New | ALBIREO PHARMA INC | $6,950,000 | – | 359,000 | +100.0% | 0.96% | – |
| SEDG | New | SOLAREDGE TECHNOLOGIES INC | $6,811,000 | – | 29,426 | +100.0% | 0.94% | – |
| GILD | New | GILEAD SCIENCES INC | $6,483,000 | – | 105,090 | +100.0% | 0.90% | – |
| New | GENERAC HLDGS INCcall | $6,342,000 | – | 35,600 | +100.0% | 0.88% | – | |
| New | ARCELLX INC | $6,271,000 | – | 334,080 | +100.0% | 0.87% | – | |
| BLU | New | BELLUS HEALTH INC NEW | $4,909,000 | – | 464,860 | +100.0% | 0.68% | – |
| New | SENTINELONE INCcall | $4,212,000 | – | 164,800 | +100.0% | 0.58% | – | |
| New | CINCOR PHARMA INC | $3,904,000 | – | 118,950 | +100.0% | 0.54% | – | |
| New | RELMADA THERAPEUTICS INCput | $3,443,000 | – | 93,000 | +100.0% | 0.48% | – | |
| New | DICE THERAPEUTICS INC | $3,101,000 | – | 152,913 | +100.0% | 0.43% | – | |
| New | DICE THERAPEUTICS INCput | $3,042,000 | – | 150,000 | +100.0% | 0.42% | – | |
| STOK | New | STOKE THERAPEUTICS INC | $2,018,000 | – | 157,200 | +100.0% | 0.28% | – |
| RUN | New | SUNRUN INC | $1,793,000 | – | 65,000 | +100.0% | 0.25% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $1,756,000 | – | 1,476,000 | +100.0% | 0.24% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $1,440,000 | – | 200,000 | +100.0% | 0.20% | – |
| New | ALTIMMUNE INCput | $1,277,000 | – | 100,000 | +100.0% | 0.18% | – | |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $1,226,000 | – | 120,000 | +100.0% | 0.17% | – |
| PSTX | New | POSEIDA THERAPEUTICS INC | $1,059,000 | – | 300,000 | +100.0% | 0.15% | – |
| MDWD | New | MEDIWOUND LTD | $958,000 | – | 688,716 | +100.0% | 0.13% | – |
| ICL | New | ICL GROUP LTD | $912,000 | – | 111,482 | +100.0% | 0.13% | – |
| EWTX | New | EDGEWISE THERAPEUTICS INC | $590,000 | – | 60,000 | +100.0% | 0.08% | – |
| U | New | UNITY SOFTWARE INC | $366,000 | – | 11,500 | +100.0% | 0.05% | – |
| CYCC | New | CYCLACEL PHARMACEUTICALS INC | $365,000 | – | 250,000 | +100.0% | 0.05% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.